30
Participants
Start Date
October 2, 2013
Primary Completion Date
August 25, 2020
Study Completion Date
April 20, 2021
IL-2
HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
Stereotactic Ablative Body Radiation Therapy
SABR dose varying from 8Gy-20Gy in 1-3 fractions
University of Texas Southwestern Medical Center, Dallas
Collaborators (1)
Prometheus Laboratories
INDUSTRY
University of Texas Southwestern Medical Center
OTHER